Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir — Tamar Tadmor (2023) | RDL Network
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir
Letter 2023 English
Authors
TT
Tamar Tadmor
GM
Guy Melamed
TP
Tal Patalon
Abstract
1 min read
Click to increase image sizeClick to decrease image size Disclosure statementNo potential conflict of interest was reported by the author(s).Author contributionsTT designed, organized, and wrote the manuscript. HA prepared the data and preprocessed the data, GM and TP, wrote the manuscript, LR designed, organized, performed the statistical analysis and wrote the manuscript.Additional informationFundingA grant from KSM- Maccabi Research and Innovation Center supported this study.
William HK Schilling, Podjanee Jittamala, James A Watson, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M. Batty, Cintia Cruz, James J. Callery, Shivani Singh, Manisaree Saroj, Varaporn Kruabkontho, Thatsanun Ngernseng, Nuttakan Tanglakmankhong, Jaruwan Tubprasert, Mohammad Yazid Abdad, Wanassanan Madmanee, Jindarat Kouhathong, Kanokon Suwannasin, Watcharee Pagornrat,
Discussion(0)
No comments yet. Be the first to comment.